期刊文献+

加味麻杏石甘汤治疗社区获得性肺炎的疗效观察 被引量:6

Efficacy of the Maxing Shigan decoction on CAP
下载PDF
导出
摘要 目的:观察加味麻杏石甘汤治疗痰热郁肺型社区获得性肺炎的临床疗效。方法:将60例社区获得性肺炎患者随机分为对照组和观察组各30例,对照组给予常规西药治疗,观察组在常规西药治疗的基础上加用加味麻杏石甘汤。比较两组的疗效、超敏C-反应蛋白(hs-CRP)、白细胞计数(WBC)、降钙素原(PCT)。结果:治疗后,观察组的疗效明显高于对照组,两组的hs-CRP、WBC、PCT水平明显低于治疗前,且观察组hs-CRP、WBC、PCT水平明显低于对照组,差异均具有统计学意义(P<0.05)。结论:常规治疗基础上联合加味麻杏石甘汤可以提高痰热郁肺型社区获得性肺炎的疗效,降低hs-CRP、WBC、PCT等炎症指标水平。 Objective: To observe the clinical effect of the Maxing Shigan decoction( 麻杏石甘汤) on community-acquired pneumonia of the Tanre Yufei type( 痰热郁肺型). Methods: 60 patients were randomly divided into the control group and observation group, 30 cases in each group. The control group was given conventional western medicine. The observation group was given the Maxing Shigan decoction more. The efficacy, hs-CRP, WBC and PCT were compared between two groups. Results: After treatment, the curative effect in the observation group was significantly higher than the control group. The levels of hs-CRP, WBC and PCT in two groups were significantly lower than those before treatment, and those in the observation group were significantly lower than those in the control group(P〈0.05). Conclusion: Routine treatment with the Maxingshigan decoction was effective on community-acquired pneumonia of the Tanre Yufei type, can reduce hs-CRP, WBC, PCT and other indicators of inflammation.
出处 《中医临床研究》 2018年第10期73-75,共3页 Clinical Journal Of Chinese Medicine
关键词 加味麻杏石甘汤 社区获得性肺炎 临床疗效 炎症指标 The Maxing Shigan decoction Community acquired pneumonia Clinical efcacy Infammatory index
  • 相关文献

参考文献7

二级参考文献63

  • 1陆权,张育才.小儿呼吸系统疾病诊治进展[J].中国实用儿科杂志,2006,21(5):323-326. 被引量:55
  • 2危重病人营养支持指导意见(2006)[J].中国实用外科杂志,2006,26(10):721-732. 被引量:174
  • 3社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006,29(10):651-655. 被引量:3040
  • 4沈晓明,王卫平.儿科学[M].7版.北京:人民卫生出版社,2009:11-13.
  • 5Mande11 LA,Wunderink RG,Anzueto A,et al. Infectious DiseasesSociety of America/American Thoracic Society guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis, 2007,44 Suppl 2 : S27-S72.
  • 6Rello J. Demographics, guidelines, and clinical experience in severe community-acquired pneumonia. Crit Care,2008, 12 Suppl 6:S2.
  • 7Martinez R, Menendez R, Reyes S,et al. Factors associated with inflammatory cytokine patterns in community-acquired pneumonia. Eur Respir J,2011,37 : 393-399.
  • 8Ramirez P, Ferrer M, Marti V, et al. Inflammatory biomarkers and prediction for intensive care unit admission in severe communityacquired pneumonia. Crit Care Med ,2011,39 : 1-7.
  • 9Gogosl C, Kotsaki A, Pelekanou A. Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection. Crit Care,2010,14 : R96-R107.
  • 10Wunderink RG, Laterre PF, Francois B, et al. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia. Am J Respir Crit Care Med,2011,183 : 1561-1568.

共引文献191

同被引文献71

引证文献6

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部